The studies of the IDIBELL and ICO researcher and UOC faculty member were key to prove that the human papillomavirus is the main cause of cervical cancer
Read moreResearchers from IDIBELL Regenerative Program has discovered that this inactivation is affected in bone marrow aged stem cells.
Read moreAptadel Therapeutics is a preclinical company co-founded by IDIBELL focused on developing a new platform for targeted therapy against cancer. This platform consists of nanoparticles loaded with therap...
Read moreEl equipo de Eva González-Suarez, del CNIO y del IDIBELL, y el equipo de Christos Sotiriou, de Instituto Jules Bordet, demuestran que un fármaco usado ya para el tratamiento de la osteoporosis promu...
Read moreA total of 44 researchers from the Bellvitge Biomedical Research Institute (IDIBELL) and Bellvitge University Hospital (HUB) sign an article in the International Journal of Infectious Disease...
Read moreEl Servicio de Medicina Intensiva del Hospital Universitario de Bellvitge participa, a través del Instituto de Investigación Biomédica de Bellvitge (IDIBELL), en el proyecto europeo ENVISION, que d...
Read moreThis tool is able to identify single-person neurodegeneration before the symptom’s appearance, which could significate a more effective and personalized medicine.
Read moreEl estudio, liderado por investigadores del IDIBELL, el Hospital Sant Joan de Déu y el CIBERER, se publica en la prestigiosa revista ‘Acta Neuropathologica’
Read moreDysregulation of RNA and protein levels, compared to normal tissues, is a consistent molecular feature of all cancers. Behind the causes of these changes, chemical modifications have recently been ide...
Read moreSmoking in water pipes and passive exposure to the smoke they produce, increase the risk of lung cancer and other cardiovascular diseases. It is for this reason that its use should be regulated and co...
Read moreLa spin-of del IDIBELL, creada en 2017 y con sede en L'Hospitalet de Llobregat, es una de las 36 empresas seleccionadas de entre las 1.406 solicitudes recibidas en la convocatoria EIC Accelerator del ...
Read moreEl grupo de quimiorresistencia del Programa PROCURE del ICO-IDIBELL, liderado por Alberto Villanueva, ha trasladado su experiencia en la generación de modelos ortotópicos de ratones en pacientes adu...
Read more